# Characteristics and Treatment Patterns of Patients with Haemophilia B Receiving Recombinant Coagulation Factor IX

**Authors:** Young-Shil Park, Tai Ju Hwang, Sang Kyu Park, Eun Jin Choi, Jeong A Park, Hee Jo Baek, Chuhl Joo Lyu, Jae Hee Lee, Mi Kyung Kim, Ji Yoon Kim, Sun Ah Lee, Boram Park, Da-Hye Kim, Sung Beom Chung, Chung-Mo Nam, Yaeji Lee, Ki Young Yoo

PMC · DOI: 10.3390/jcm14134555 · Journal of Clinical Medicine · 2025-06-26

## TL;DR

This study examines how Korean patients with Haemophilia B are treated with Factor IX and finds that higher doses and sustained prophylaxis reduce bleeding events.

## Contribution

The study provides real-world evidence on the effectiveness of Factor IX dosing and adherence in managing Haemophilia B in Korea.

## Key findings

- Prophylaxis with Factor IX significantly reduces annualized bleeding events.
- Higher monthly Factor IX doses are associated with lower bleeding risk.
- Adherence to treatment does not independently affect bleeding outcomes.

## Abstract

Introduction: In Haemophilia B, guideline-level factor IX (FIX) prophylaxis is recommended, but real-world dosing and adherence vary. Aim: To assess treatment patterns, adherence, FIX dosing, and their associations with bleeding events in Korean patients. Methods: We conducted a retrospective chart review and one-time survey of 130 Korean patients with haemophilia B treated with FIX for ≥12 months at 12 centers (June 2022–May 2023). A total of forty-seven patients (36.2%) received prophylaxis (≥90 IU/kg/week for ≥45 weeks); the remainder were managed non-prophylactically. Annualized bleeding events (ABEs) were analyzed using negative binomial regression, and monthly bleeds with a generalized linear mixed model. Covariates with p < 0.10 and clinical relevance were included in multivariable models. Results: The prophylaxis group showed significantly fewer ABEs (incidence rate ratio [IRR]: 0.383, p = 0.011). Each 100 IU/kg monthly dose increment reduced bleed risk (IRR: 0.692, p < 0.001). Adherence showed no independent association with bleeding in adjusted models. Conclusions: Bleed prevention in haemophilia B is driven more by delivered FIX exposure than by regimen label. Study-defined sustained prophylaxis remains underused and under-dosed. Individualized dosing and continuous adherence monitoring are essential to close this treatment gap and improve outcomes.

## Full-text entities

- **Genes:** F9 (coagulation factor IX) [NCBI Gene 2158] {aka F9 p22, FIX, HEMB, P19, PTC, THPH8}
- **Diseases:** Haemophilia B (MESH:D002836), Bleed (MESH:D006470)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12250204/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12250204/full.md

## References

26 references — full list in the complete paper: https://tomesphere.com/paper/PMC12250204/full.md

---
Source: https://tomesphere.com/paper/PMC12250204